As indeed previously reported, blocking VEGFR1 or its specific ligand PlGF is less detrimental compared to VEGF-A blockade [36, 37], which, given the vital role of VEGF-A/VEGFR2 pathway in the physiological homeostasis of vessels [38], is responsible of the several side effects observed not only in cancer, but also in ocular neovascular diseases [6, 7]. The gene discussed is PGF; the disease is cancer.